BioXcel Therapeutics (NASDAQ:BTAI) posted its quarterly earnings data on Friday. The company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.05), MarketWatch Earnings reports.
BTAI traded down $0.15 during trading on Friday, reaching $5.90. 82,078 shares of the stock traded hands, compared to its average volume of 27,947. BioXcel Therapeutics has a 12 month low of $5.00 and a 12 month high of $14.79.
A number of institutional investors and hedge funds have recently modified their holdings of BTAI. Creative Planning bought a new stake in BioXcel Therapeutics during the third quarter valued at $102,000. BlackRock Inc. bought a new stake in BioXcel Therapeutics during the second quarter valued at $137,000. Millennium Management LLC bought a new stake in BioXcel Therapeutics during the first quarter valued at $316,000. Point72 Asset Management L.P. boosted its position in BioXcel Therapeutics by 10.7% during the second quarter. Point72 Asset Management L.P. now owns 65,809 shares of the company’s stock valued at $605,000 after acquiring an additional 6,358 shares during the last quarter. Finally, Artemis Investment Management LLP boosted its position in BioXcel Therapeutics by 1.3% during the third quarter. Artemis Investment Management LLP now owns 1,254,853 shares of the company’s stock valued at $9,700,000 after acquiring an additional 16,358 shares during the last quarter. 23.90% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have commented on BTAI. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of BioXcel Therapeutics in a research report on Wednesday, August 1st. Canaccord Genuity reaffirmed a “buy” rating and set a $21.00 price target on shares of BioXcel Therapeutics in a research report on Friday, August 10th. Finally, Zacks Investment Research cut shares of BioXcel Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. BioXcel Therapeutics presently has an average rating of “Buy” and an average target price of $18.67.
WARNING: “BioXcel Therapeutics (BTAI) Announces Earnings Results, Misses Expectations By $0.05 EPS” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/10/bioxcel-therapeutics-btai-announces-earnings-results-misses-expectations-by-0-05-eps.html.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
See Also: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.